A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

Registry ID

EUCTR2013-003660-31

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Alvine Pharmaceuticals, Inc.

Start date

2013-11-27

Completion date

2015-05-28

Last update

2026-08-16

Conditions

• Celiac Disease

Summary

The primary objective is to determine the effect of different dose levels of ALV003 administered for 12 weeks on mucosal morphometry as measured by the villus height to crypt depth ratio (Vh:Cd).

Locations

• , , UK
• , , Ireland
• , , Finland
• , , Norway

Related clinical trials

• Study of DONQ52 in Active Celiac Disease
• Liver Steatosis and Fibrosis in Non-Celiac Wheat Sensitivity Patients: a Prospective Study
• Nutrition and Physical Activity Education in Children With Celiac Disease
• A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
• Tissue Destruction and Healing in Celiac Disease
• VTP-1000 in Adults With Celiac Disease

View on source registry